Abstract
The pancreatic ductal adenocarcinoma (PDAC) has a bad prognosis with delayed diagnosis that significantly impedes the use of therapeutic resection. Similarly, colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell dissemination has taken place in the liver. A main reason for this situation is the already resistant or newly resistant tumors to all conventional current therapies. Here, we report the re-sensitization of PDAC and CRC cells to chemotherapy, radiotherapy and/or immune checkpoint inhibitors by the newly developed inhibitors that target the activity of the proprotein convertases, enzymes involved in the biological activation/maturation of various protein precursors crucial for the malignant phenotype of PDAC and CRC tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
